Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies - Related parties (Details)

v3.10.0.1
Summary of Significant Accounting Policies - Related parties (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Related parties        
Research and Development Expense $ 23,484,000 $ 24,034,000 $ 75,500,000 $ 62,240,000
Immunocore        
Related parties        
Research and Development Expense   $ 67,000   $ 781,000